Takeda is the latest big pharma paying its way into Alnylam's not-so-exclusive club, with the firm having agreed to pay Alnylam $150 million upfront in exchange for worldwide, non-exclusive access to its RNA interference therapeutics platform technology in two therapeutic areas: oncology and metabolic disease
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.
Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.
Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.
